Provectus Pharmaceuticals, Inc. (PVCT) Starts Presentation at 2nd Annual Marcum MicroCap Conference
Provectus Pharmaceuticals is focused on developing oncology and dermatology therapies. The company’s novel oncology drug, PV-10, is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. PVCT’s oncology focus is on melanoma, breast cancer and cancers of the liver. The company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. For more information visit the company’s Web site at www.pvct.com
Let us hear your thoughts below:
The Marcum MicroCap Conference is a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The two-day 2016 conference will include feature presentations by CEOs and CFOs from seven principal industry sectors, expert panels moderated by industry leaders, and the opportunity to meet with management of presenting companies on a one-on-one basis. Marcum is partnered with KCSA Strategic Communications to present this year's Marcum MicroCap Conference.
This entry was posted in
Marcum MicroCap. Bookmark the
permalink.
